Thyroid Pills Recalled: Superpotent Dosage Risks

Vitruvias Therapeutics has initiated a voluntary recall of one lot of its 30mg thyroid tablets, identified as lot number 504950. Federal regulators announced this week that these tablets may be "superpotent." This heightened potency increases the risk of developing hyperthyroidism, a condition characterized by an overactive thyroid gland.

The recalled medication was distributed nationwide to direct accounts from January 31, 2025, to September 30, 2025. The Food and Drug Administration warned that consuming these tablets could result in significant health issues. Symptoms may include noticeable weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, and heart rhythm disturbances.

Certain populations, including the elderly, pregnant women, and infants, are considered to be at the greatest risk from exposure to the superpotent tablets. Out of the 3,655 units distributed, 1955 were sold. Vitruvias Therapeutics has begun notifying its wholesalers to halt distribution and arrange for the destruction of the affected product.

Despite the recall, the company has not received any reports of negative health impacts associated with the recalled tablets. These medications are typically prescribed to treat hypothyroidism, or an underactive thyroid. Patients currently using the affected lot are strongly advised not to discontinue their medication without first consulting with their healthcare provider.